Introduction: Who Needs Diagnostic Testing

Diagnostic testing for metastatic non-small cell lung cancer becomes important when certain warning signs appear, or when someone has known risk factors for lung cancer. Anyone experiencing symptoms such as a persistent cough that doesn’t go away or gets worse over time, coughing up blood or rust-colored spit, chest pain that worsens with deep breathing or coughing, unexplained weight loss, shortness of breath, hoarseness, or ongoing tiredness should discuss these concerns with their healthcare provider^[1][4].

Many people with non-small cell lung cancer do not experience symptoms in the early stages because the lungs do not have pain receptors. This means the cancer can grow and even spread to other parts of the body before any noticeable symptoms appear^[1][9]. Because of this silent progression, the disease is often diagnosed at an advanced stage when it has already metastasized, which is why early detection through testing is so critical.

People with certain risk factors should be especially attentive to any changes in their health. The most common risk factor is a history of smoking, but other factors include exposure to asbestos, radon gas, or metal and mineral dust, having respiratory conditions like chronic obstructive pulmonary disease (COPD) or pulmonary fibrosis, previous radiation therapy to the breast or chest, and a family history of lung cancer^[1][3]. If you fall into any of these categories and develop concerning symptoms, seeking diagnostic testing promptly can make a significant difference.

When lung cancer spreads to distant organs, which is what makes it metastatic, additional symptoms may develop depending on where the cancer has traveled. These can include bone pain (especially in the back or hips), difficulty swallowing, swelling of the face or neck, bulging veins on the neck and head, lumps in the neck or above the collarbone, yellowing of the skin and eyes, headaches, weakness or numbness in an arm or leg, dizziness, balance problems, or seizures^[4][12]. If any of these symptoms occur, immediate medical attention is necessary.

It’s important to remember that experiencing these symptoms does not automatically mean you have lung cancer. However, it is very important to talk to your healthcare team if you notice any of these changes, as they have the knowledge and tools needed to make an appropriate diagnosis^[4].

Diagnostic Methods for Identifying NSCLC

When a healthcare provider suspects non-small cell lung cancer, they will begin with a thorough physical examination and take a detailed medical history. They will ask about your symptoms, how long you’ve had them, your smoking history, occupational exposures, and any family history of cancer. This initial assessment helps guide which tests should be performed next^[1][11].

Imaging Tests

Imaging tests are often the first step in visualizing what might be happening inside your lungs and chest. A chest X-ray is usually the initial imaging test performed when lung cancer is suspected. This simple test can reveal abnormal masses or nodules in the lungs. However, a chest X-ray alone is not sufficient to confirm a cancer diagnosis or determine if it has spread^[1].

Computed tomography (CT) scans of the chest provide much more detailed images than X-rays. CT scans use specialized equipment to create cross-sectional images of the body, allowing doctors to see the size, shape, and location of any tumors, as well as whether lymph nodes appear enlarged. CT scans are critical for understanding the extent of the disease^[1][11].

Magnetic resonance imaging (MRI) scans of the brain are commonly performed when there is suspicion that lung cancer has spread to the brain. Because the brain is one of the common sites where metastatic non-small cell lung cancer travels, this test helps detect any tumors or abnormalities in brain tissue^[1][11].

Positron emission tomography (PET) scans are another important imaging tool. In a PET scan, a small amount of radioactive sugar is injected into the body. Cancer cells, which tend to use more sugar than normal cells, show up as brighter spots on the scan. PET scans are particularly useful for determining whether cancer has spread to lymph nodes or other parts of the body^[1].

Biopsy Procedures

If imaging tests suggest the presence of cancer, a biopsy is necessary to confirm the diagnosis. A biopsy involves removing a small sample of tissue or cells from the suspicious area so it can be examined under a microscope by a specialist called a pathologist. The pathologist determines whether cancer cells are present and, if so, what type of lung cancer it is^[1][3].

There are several ways to obtain a biopsy sample. A lung biopsy can be performed using different techniques depending on where the tumor is located. One common method is bronchoscopy, where a thin, flexible tube with a camera is inserted through the nose or mouth, down the throat, and into the airways. This allows the doctor to see inside the airways and take tissue samples from suspicious areas^[1][11].

Another approach is video-assisted thoracic surgery (VATS), a minimally invasive surgical technique that helps the provider get a better look inside the chest and obtain tissue samples. In some cases, a needle biopsy may be performed, where a needle is inserted through the chest wall to extract tissue from a lung mass^[1][11].

Once cancer cells are identified, additional testing is done on the biopsy sample to look for specific genetic changes or mutations in the cancer cells. These tests, called molecular or biomarker testing, can reveal whether the tumor has abnormalities in genes such as EGFR, ALK, ROS1, or KRAS. Knowing whether these mutations are present is crucial because it helps doctors determine which targeted therapies might be most effective for treatment^[3][13].

Determining the Extent of Spread

After non-small cell lung cancer has been diagnosed, additional tests are performed to determine if and where the cancer has spread. This process is called staging. Staging is essential because it tells doctors how advanced the cancer is and helps guide treatment decisions^[3].

Metastatic non-small cell lung cancer, also called stage 4 or stage IV, means the cancer has spread beyond the lungs to other parts of the body. The most common sites where this cancer spreads include the bones, the other lung, the brain, adrenal glands (which are near the kidneys), liver, and lymph nodes outside the chest^[2][5].

According to research, among patients with metastatic non-small cell lung cancer, approximately 34 percent have bone metastasis, 32 percent have lung metastasis, 28 percent have brain metastasis, 17 percent have adrenal gland metastasis, 13 percent have liver metastasis, and about 10 percent have spread to lymph nodes outside the chest area^[5].

To check for metastasis, imaging tests are performed on different parts of the body. CT scans of the chest, abdomen, and pelvis can reveal whether cancer has spread to organs such as the liver, adrenal glands, or lymph nodes. Bone scans or PET scans can detect cancer that has traveled to the bones. MRI scans of the brain are used to look for brain metastases^[1][11].

Diagnostics for Clinical Trial Qualification

Clinical trials are research studies that test new treatments or combinations of treatments for cancer. Participating in a clinical trial can give patients access to cutting-edge therapies that are not yet widely available. However, to participate in a clinical trial, patients must meet specific criteria, and diagnostic tests play a key role in determining eligibility^[3][10].

Clinical trials for metastatic non-small cell lung cancer typically require confirmation of the diagnosis through a biopsy. The biopsy sample must show that the patient has non-small cell lung cancer, as opposed to small cell lung cancer or another type of tumor. Pathology reports that describe the type of cancer cells (such as adenocarcinoma, squamous cell carcinoma, or large cell carcinoma) are essential for trial enrollment^[3].

Many clinical trials also require molecular or biomarker testing to identify specific genetic mutations in the tumor. For example, trials testing new targeted therapies for patients with EGFR mutations, ALK rearrangements, or other genetic changes will only enroll patients whose tumors have those specific mutations. This ensures that the treatment being tested is appropriate for that patient’s type of cancer^[3][13].

Imaging tests such as CT scans, PET scans, or MRI scans are standard requirements for clinical trial enrollment. These scans serve as a baseline measurement of the size and location of tumors. Throughout the trial, repeat imaging is performed at regular intervals to assess whether the treatment is working, whether tumors are shrinking, staying the same, or growing^[3].

Blood tests are also commonly required for clinical trial qualification. These tests check for overall health and organ function. For instance, doctors need to know how well your liver and kidneys are working, as many cancer treatments are processed by these organs. Blood tests may also measure levels of certain proteins or markers that can indicate disease activity or response to treatment^[3].

In addition to these diagnostic tests, clinical trials typically assess a patient’s performance status, which is a measure of how well a person can carry out daily activities. Performance status is often evaluated using standardized scales that rate a patient’s ability to care for themselves, work, and be active. This helps researchers understand whether a patient is healthy enough to tolerate the experimental treatment being studied^[3][5].

Some trials may have additional diagnostic requirements depending on the treatment being tested. For example, if a trial is testing a treatment specifically for brain metastases, an MRI of the brain would be required. If the trial focuses on a particular mutation, such as the EGFR exon 20 insertion mutation, specialized genetic testing to confirm that mutation would be necessary^[13].

It’s important to understand that meeting the diagnostic criteria for a clinical trial does not guarantee enrollment, as trials often have limited spaces and additional eligibility requirements related to age, prior treatments, and other health conditions. However, working with your oncology team to gather all necessary diagnostic information can improve your chances of qualifying for a trial that might benefit you.